Matinas Biopharma (NYSEAMERICAN:MTNB) Trading Down 0.4% – Should You Sell?

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNBGet Free Report)’s share price traded down 0.4% during trading on Friday . The stock traded as low as $0.7655 and last traded at $0.79. 19,355 shares traded hands during mid-day trading, a decline of 37% from the average session volume of 30,777 shares. The stock had previously closed at $0.7929.

Matinas Biopharma Stock Down 0.4%

The firm has a market capitalization of $5.06 million, a P/E ratio of -0.23 and a beta of 1.32. The company has a fifty day simple moving average of $1.24 and a 200 day simple moving average of $1.28.

Matinas Biopharma (NYSEAMERICAN:MTNBGet Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter.

Matinas Biopharma Company Profile

(Get Free Report)

Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D.

Read More

Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.